Publications by authors named "Atul B. Mehta"

Claim this Profile
T
Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.
Michael Beck, Uma Ramaswami, Elizabeth Hernberg-Ståhl, Derralynn A Hughes, Christoph Kampmann, Atul B Mehta

Orphanet J Rare Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of plasma lyso-Gb for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.
Daniel G Bichet, Johannes M Aerts, Christiane Auray-Blais, Hiroki Maruyama, Atul B Mehta

Genet Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Assessment of plasma lyso-Gb for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.
Daniel G Bichet, Johannes M Aerts, Christiane Auray-Blais, Hiroki Maruyama, Atul B Mehta

Genet Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
Matthew C Reed, Yehudit Bauernfreund, Niamh Cunningham, Brendan Beaton, Atul B Mehta

Gene· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease.
Matthew C Reed, Capucine Schiffer, Simon Heales, Atul B Mehta, Derralynn A Hughes

Mol Genet Metab· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Dylan J Mac Lochlainn, Douglas G J McKechnie, Atul B Mehta, Derralynn A Hughes

Mol Genet Metab· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature?
Alison S Thomas, Atul B Mehta

Expert Opin Med Diagn· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients.
James Donaldson, Wasim S Khan, Hiteshkumar Tailor, Derralynn A Hughes, Atul B Mehta

Hip Int· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).
Hatim Y Ebrahim, Robert J Baker, Atul B Mehta, Derralynn A Hughes

J Inherit Metab Dis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.
Perry Elliott, Robert Baker, Ferdinando Pasquale, Giovanni Quarta, Hatim Ebrahim, Atul B Mehta

Heart· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated disease severity scoring system for Fabry disease.
Edward H Giannini, Atul B Mehta, Max J Hilz, Michael Beck, Daniel G Bichet

Mol Genet Metab· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.
Anoop D Shah, Andrew J B Watts, Atul B Mehta, Ashutosh D Wechalekar

Int J Hematol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
Gareth Gerrard, Terry D Butters, Kanagasabai Ganeshaguru, Atul B Mehta

Eur J Pharmacol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemorheology in Gaucher disease.
Bridget E Bax, Linda Richfield, Murray D Bain, Atul B Mehta, Ronald A Chalmers

Eur J Haematol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Santhosh Narat, Jagdeesh Gandla, Allan Victor Hoffbrand, Robert George Hughes, Atul B Mehta

Haematologica· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.
Jaymin S Shah, Derralynn A Hughes, Bhavesh Sachdev, Maite Tome, Deirdre Ward, Atul B Mehta

Am J Cardiol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide.
Alexandra J Marks, Margaret S Cooper, Robert J Anderson, Kim H Orchard, Geoffrey Hale, Atul B Mehta

Cancer Res· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Gareth Gerrard, Elspeth Payne, Robert J Baker, Dylan T Jones, Michael Potter, Atul B Mehta

Haematologica· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.
Dylan T Jones, Elena Addison, Janet M North, Mark W Lowdell, A Victor Hoffbrand, Atul B Mehta

Blood· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia.
Veronique M Duke, Domenica Gandini, Paul D Sherrington, Ke Lin, Bridget Heelan, Atul B Mehta

Haematologica· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of lysosomal storage disorders.
Atul B Mehta, Susan Lewis, Christine Laverey

BMJ· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Dylan T Jones, Kanagasabai Ganeshaguru, Wayne A Mitchell, Letizia Foroni, Robert J Baker, Atul B Mehta

Br J Haematol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis.
Dylan T Jones, Kanagasabai Ganeshaguru, Robert J Anderson, Trevor R Jackson, K Richard Bruckdorfer, Atul B Mehta

Blood· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Kanagasabai Ganeshaguru, Ranmohan G Wickremasinghe, Dylan T Jones, Mathew Gordon, Steve M Hart, Atul B Mehta

Haematologica· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infusional 5-fluorouracil in Cutaneous Leukaemia: a Novel Palliative Therapy in Haematological Malignancy; Malignancy.
Clare P. F. Taylor, Atul B. Mehta

Hematology· January 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis